APR 10, 2019 10:30 AM PDT

Better Knowledge, Better Care: Precision Medicine for Any Cancer, Any Assay, on Your Platform

Sponsored by: QIAGEN
Speakers
  • Chief Scientific Officer, N-of-One, A QIAGEN Company
    Biography
      Sheryl Krevsky Elkin, PhD, is the Chief Scientific Officer at N-of-One. As an early member of the N-of-One team, Dr. Elkin has led the interpretation of thousands of patient cases, establishing a rigorous process for the analysis of scientific and clinical evidence and presentation of molecular and clinical evidence to physicians to help guide their therapeutic decisions. For the past nine years, Dr. Elkin has taken a lead role in the development of the N-of-One clinical interpretation methodology to support clinicians in identifying therapeutic strategies specific to each patient. Prior to joining N-of-One, Dr. Elkin completed her postdoctoral fellowship at the Massachusetts Institute of Technology's Center for Cancer Research, where she earned a fellowship from the Leukemia and Lymphoma Society. Dr. Elkin earned her doctorate in Biological and Biomedical Sciences from Harvard Medical School and an A.B. in Biology and Music from Amherst College, graduating Phi Beta Kappa and summa cum laude, with High Distinction in Biology.
    • Vice President, Biomedical Informatics, QIAGEN
      Biography
        Dan Richards is Vice President, Biomedical Informatics at QIAGEN, where he focuses on the automated interpretation of molecular variation in the context of current clinical evidence. Dan earned his Ph.D. in Human Genetics from Stanford University and co-founded Ingenuity Systems, whose analysis applications and manually-curated knowledge base of peer-reviewed scientific literature are used by scientists and clinicians worldwide to interpret genomic data in the context of current biomedical knowledge.

      Abstract

      QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, we will present our clinical decision support solutions, QIAGEN Clinical Insight and N-of-One, that allow you to optimize and scale your pipeline for clinical interpretation of genetic variants—from sequence data to report sign-off—without sacrificing accuracy. With the automated implementation of expert guidelines for pathogenicity and actionability based on an expansive knowledgebase derived from >20 years of manual curation, and now with N-of-One bringing in report-ready text tailored to the assay, supporting the clinical options with the most relevant evidence from the literature, QIAGEN provides a platform that provides the best-in-class evidence enabling clarity and confidence in reporting.

      Learning Objectives: 

      1. Struggling to keep pace with the latest clinical findings? Learn how you can remain up-to-date on the increasing number of publications, biomarker data, and remain informed of changing clinical trial availability and treatment options with the combined QIAGEN Knowledge Base and N-of-One’s MarkerMine, now the world’s largest clinical evidence database providing the most relevant and timely information needed in your clinical decision making. 
      2. Looking for an automated NGS variant interpretation and reporting solution? Discover how to automate, scale and standardize your NGS variant interpretation and reporting according to the latest professional guidelines (ACMG/AMP, AMP/ASCO/CAP, etc.)
      3. Learn about the flexible options for standardized and consistent clinical NGS reporting that suits your needs


      Show Resources
      You May Also Like
      MAY 11, 2021 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      MAY 11, 2021 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      JUN 09, 2021 7:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
      APR 01, 2021 8:00 AM PDT
      C.E. CREDITS
      APR 01, 2021 8:00 AM PDT
      Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
      NOV 16, 2020 8:00 AM PST
      C.E. CREDITS
      NOV 16, 2020 8:00 AM PST
      Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
      DEC 02, 2020 8:00 AM PST
      C.E. CREDITS
      DEC 02, 2020 8:00 AM PST
      DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
      MAR 16, 2021 10:00 AM PDT
      C.E. CREDITS
      MAR 16, 2021 10:00 AM PDT
      Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
      APR 10, 2019 10:30 AM PDT

      Better Knowledge, Better Care: Precision Medicine for Any Cancer, Any Assay, on Your Platform

      Sponsored by: QIAGEN

      Specialty

      Cancer Research

      Cancer Diagnostics

      Immunology

      Clinical Diagnostics

      Drug Discovery

      Personalized Medicine

      Biotechnology

      Immunity

      Antibodies

      Immunotherapy

      Toxicology

      Flow Cytometry

      Immuno-Oncology

      Dna Sequencing

      Cell Culture

      Geography

      North America67%

      Europe33%

      Registration Source

      Website Visitors100%

      Job Title

      Student33%

      Research Scientist33%

      Lab Management33%

      Organization

      General Laboratory33%

      Hospital33%

      Academic Institution33%


      Show Resources
      Loading Comments...
      Show Resources
      Attendees
      • See more